| Drug Type Small molecule drug | 
| Synonyms Malol, Prunol, Urson + [2] | 
| Action inhibitors | 
| Mechanism Akt inhibitors(Proto-oncogene proteins c-akt inhibitors), Enzymes inhibitors, FADS2 inhibitors(fatty acid desaturase 2 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC30H48O3 | 
| InChIKeyWCGUUGGRBIKTOS-GPOJBZKASA-N | 
| CAS Registry77-52-1 | 
| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | Ursolic Acid | - | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Metabolic Syndrome | Phase 2 | Mexico  | 01 Sep 2014 | |
| Stomach Cancer | Preclinical | China  | 01 Jul 2025 | |
| Parkinson Disease | Preclinical | India  | 24 Jun 2025 | |
| Parkinson Disease | Preclinical | India  | 24 Jun 2025 | |
| Non-Small Cell Lung Cancer | Preclinical | China  | 27 May 2025 | |
| Castration-Resistant Prostatic Cancer | Preclinical | United States  | 28 Apr 2025 | 
| Phase 2 | 10 | Strength Training+Ursolic Acid (UA and Exercise in Paraplegia Group) | ryrzcttciy(jjabdsgkvc) = suvrdfrnbs kjwxmidgdd  (ytweuckzog, 2642.65) View more | - | 21 May 2025 | ||
| (UA in Tetraplegia Group) | ryrzcttciy(jjabdsgkvc) = hujeefosuv kjwxmidgdd  (ytweuckzog, 1885.21) View more | ||||||
| Phase 2/3 | - | (UA supplementation) | disjmnphmr(hbzggbhrcp) = fhvmkyqlmo aygyqfuhsi (xakxibbvjy ) | Negative | 01 Aug 2021 | ||
| (Placebo supplementation) | - | ||||||
| Phase 2 | 24 | (Ursolic Acid) | axthwzexos(llejlbdojh) = orvvtgboub etrxtourzj  (vasptedflm, 1.2) View more | - | 08 Oct 2020 | ||
| Placebo (Placebo) | axthwzexos(llejlbdojh) = zahzfakwaj etrxtourzj  (vasptedflm, 1.4) View more | 





